EP Patent

EP1086694A2 — Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound

Assigned to Esteve Pharmaceuticals SA · Expires 2001-03-28 · 25y expired

What this patent protects

The pharmaceutical formulation consists of a number of pellets that comprise an inert nucleus, a layer with the active ingredient, one or more intermediate layers that comprise at least a system of modified release, and an external layer of enteric coating. These pellets can be o…

USPTO Abstract

The pharmaceutical formulation consists of a number of pellets that comprise an inert nucleus, a layer with the active ingredient, one or more intermediate layers that comprise at least a system of modified release, and an external layer of enteric coating. These pellets can be obtained applying the different layers by means of fluid bed coaling techniques using aqueous solutions or suspensions of the components of such layers. The pharmaceutical formulations can be hard gelatin capsules or tablets and are suitable for use in the prevention and treatment of disorders related to abnormal gastric acid secretion.

Drugs covered by this patent

Patent Metadata

Patent number
EP1086694A2
Jurisdiction
EP
Classification
—
Expires
2001-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Esteve Pharmaceuticals SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.